The first release, which was discussed in a scientific paper published online on Sunday by the journal Nature Biotechnology, took place in the Cayman Islands in the Caribbean in 2009 and caught the international scientific community by surprise. Oxitec has subsequently released the modified mosquitoes in Malaysia and Brazil.
Luke Alphey, the chief scientist at Oxitec, said the company had left the review and community outreach to authorities in the host countries.
“They know much better how to communicate with people in those communities than we do coming in from the U.K.” he said.
Dr. Alphey was a zoology researcher at Oxford before co-founding Oxitec in 2002. The company has raised about $24 million from investors, including Oxford, he said. A major backer is East Hill Advisors, which is run by the New England businessman Landon T. Clay, former chief executive of Eaton Vance, an investment management firm.
Oxitec says its approach is an extension of a technique used successfully for decades to suppress or even eradicate pests, which involves the release of millions of sterile insects that mate with wild ones, producing no offspring.
But the technique has not been successfully used for mosquitoes, in part because the radiation usually used to sterilize the insects also injures them, making it difficult for them to compete for mates against wild counterparts.
Oxitec has created Aedes aegypti mosquitoes, the species that is the main transmitter of the dengue and yellow fever viruses, containing a gene that will kill them unless they are given tetracycline, a common antibiotic.
In the lab, with tetracycline provided, the mosquitoes can be bred for generations and multiplied. Males are then released into the wild, where tetracycline is not available. They live long enough to mate but their progeny will die before adulthood.
The study published on Sunday looked at how successfully the lab-reared, genetically modified insects could mate. About 19,000 engineered mosquitoes were released over four weeks in 2009 in a 25-acre area on Grand Cayman island.
Based on data from traps, the genetically engineered males accounted for 16 percent of the overall male population in the test zone, and the lethal gene was found in almost 10 percent of larvae. Those figures suggest the genetically engineered males were about half as successful in mating as wild ones, a rate sufficient to suppress the population.
Oxitec has already said a larger trial on Grand Cayman island in 2010 reduced the population of the targeted mosquito by 80 percent for three months. That work has not yet been published.
Dr. Alphey said the technique was safe because only males were released, while only females bite people and spread the disease, adding that it should have little environmental impact. “It’s exquisitely targeted to the specific organism you are trying to take out,” he said.
The company is focusing on dengue fever rather than malaria because a single mosquito species is responsible for most of its spread, while many species carry malaria. Also, unlike for malaria, there are no drugs to treat dengue, and bed nets do not help prevent the disease because the mosquito bites during the day.
There are 50 million to 100 million cases of dengue each year, with an estimated 25,000 deaths. The disease causes severe flulike symptoms and occasionally, hemorrhagic fever.
The Oxitec technique, however, is not foolproof.
Alfred M. Handler, a geneticist at the Agriculture Department in Gainesville, Fla., said the mosquitoes, while being bred for generations in the lab, can evolve resistance to the lethal gene and might then be released inadvertently.
Todd Shelly, an entomologist for the Agriculture Department in Hawaii, said in a commentary published on Sunday by Nature Biotechnology that 3.5 percent of the insects in a lab test survived to adulthood despite presumably carrying the lethal gene.
Also, the sorting of male and female mosquitoes, which is done by hand, can result in up to 0.5 percent of the released insects being female, the commentary said. If millions of mosquitoes were released, even that small percentage of females could lead to a temporary increase in disease spread.
Oxitec and a molecular biologist, Anthony A. James of the University of California, Irvine, say they have developed a solution — a genetic modification that makes female mosquitoes, but not males, unable to fly. The grounded females cannot mate or bite people, and separating males from females before release would be easier.
In a test in large cages in Mexico, however, male mosquitoes carrying this gene did not mate very successfully, said Stephanie James, director of science at the Foundation for the National Institutes of Health, which oversaw the project.
In Arizona, pink bollworms sterilized by radiation have already helped suppress the population of that pest. To monitor how well the program is working, the sterile bugs are fed a red dye. That way, researchers can tell if a trapped insect is sterile or wild.
But the dye does not always show up, leading to false alarms that wild bollworms are on the loose. Giving the sterilized bugs a coral gene that makes them glow with red fluorescence is a better way to identify them, said Bruce Tabashnik, an entomologist at the University of Arizona. He is an author of a report on the field trial published in the journal PLoS One in September.
Experts assembled by the World Health Organization are preparing guidelines on how field tests of genetically modified insects should be conducted. Proponents hope the field will not face the same opposition as biotechnology crops.
“You don’t eat insects,” said Dr. James of the Foundation for the National Institutes of Health. “This is being done for a good cause.”
Andrew Pollack, NY Times